Human Immunodeficiency Virus (HIV1) Infection Market to Grow at a CAGR of 5.20% During 2026-2035

Human Immunodeficiency Virus (HIV1) Infection Market Overview

Human immunodeficiency virus type 1 (HIV-1) ranks as the most common type of HIV which destroys the CD4 immune cells, thereby attacking the body's immune system. The market is driven by the increasing cases of HIV-1, expanding treatment options, and substantial investments to advance HIV care. The market also benefits from the introduction of affordable generic drugs and advanced antiretroviral therapies. Moreover, the rising healthcare expenditure, robust regulatory support, and heightened public awareness are projected to impact the market dynamics.

Key Findings

• The global HIV burden remains high, with around 39.9 million people living with HIV, approximately 1.3 million new infections, and about 630,000 HIV-related deaths recorded in 2023, sustaining demand for antiretroviral therapy and prevention.
• Long-acting HIV prevention reached a milestone in 2025, with the first twice-yearly injectable pre-exposure prophylaxis gaining US regulatory approval, cutting dosing from a daily pill or bi-monthly injection to two administrations a year and reshaping the prevention landscape.
• The oral long-acting prevention frontier is advancing, with US regulators in 2026 accepting a filing for a once-weekly oral PrEP formulation, a potential first-in-class long-acting pill, with a decision expected in early 2027.

Human Immunodeficiency Virus (HIV1) Infection Market Demand Drivers

In 2023, around 39.9 million individuals were living with the human immunodeficiency virus, with approximately 1.3 million people estimated to acquire the infection in the year. Further, about 630,000 people died due to HIV-related causes. The rising prevalence of HIV-1 infection, with ongoing transmission reported in all countries globally, is propelling the demand for antiretroviral therapy and preventive measures, thus contributing to the overall market growth.

Human Immunodeficiency Virus (HIV1) Infection Market Segmentation Analysis

The Drug Class Segment is Setokk to Witness Significant Growth in the Forecast Period

Based on the drug class, the market segmentation includes nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, among others. Protease inhibitors, such as darunavir and atazanavir, hold a significant market share due to their efficacy in the management of treatment-resistant HIV. These medications are taken in combination with other drugs for patients who have developed resistance to the other drug classes. On the other hand, integrase inhibitors are quickly gaining significant market demand owing to their effectiveness, fewer side effects, and simple dose regimens.

The market report also offers insights based on the route of administration, end user, distribution channel, and region.

Human Immunodeficiency Virus (HIV1) Infection Market: Competitive Landscape

• In June 2026, the FDA accepted Gilead's filing for a once-weekly oral formulation of lenacapavir (Yeztugo, 300 mg tablet) for HIV prevention, with a decision date set for February 2027, positioning it as a potential first long-acting oral PrEP option.
• ViiV Healthcare continues to lead long-acting HIV therapy with its cabotegravir franchise, including Apretude for bi-monthly injectable PrEP and Cabenuva for long-acting treatment, competing directly with Gilead's newer prevention options.
• Other players include Cipla, Genentech, AbbVie, Boehringer Ingelheim, Sanofi, and Bristol Myers Squibb, spanning branded antiretrovirals and lower-cost generic HIV treatments.

Human Immunodeficiency Virus (HIV1) Infection Market Analysis by Region

The United States Covers a Substantial Market Share

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the leading markets which can be attributed to the significant burden of HIV infections and the rising emphasis on HIV care in the region. The market also benefits from the presence of a well-established healthcare system and key market players, stimulating growth and innovation in this regional market. Additionally, the rising entry of generic antiretroviral medications is anticipated to boost the market expansion in the country in the forecast period.

Key Offerings of the Report

• The Expert Market Research report gives an overview of the market for human immunodeficiency virus (HIV1) infection for the time span of (2019-2025) and (2026-2035).
• The report also offers historical (2019-2025) and forecast (2026-2035) market information for the drug class, route of administration, end user, distribution channel, and region of the market.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790